London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings
CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully developing an oral therapy could set Pharvaris apart.